Blackstone and TPG completed their acquisition of Hologic, taking the women's health diagnostics company private and naming Joe Almeida, former CEO of Baxter International, as chief executive, according to 360Dx and GenomeWeb.
The deal removes a publicly traded player in molecular diagnostics from the market. Hologic's Panther automated testing platform and Aptima assay portfolio, including its Aptima HPV test for cervical cancer screening, now operate under private ownership. Voice of Healthcare confirmed the transaction's completion.
Almeida's appointment signals potential operational changes. At Baxter, he focused on cost restructuring and portfolio rationalization. Lab directors using Panther instruments for high-volume infectious disease and women's health testing will watch for changes to service contracts, assay pricing, or R&D; investment in the platform's test menu.
In cervical cancer screening, Hologic's Aptima HPV assay competes with Roche's cobas HPV test and BD's Onclarity. The company's investment trajectory under public ownership included steady expansion of Panther's menu and installed base. Whether Blackstone and TPG maintain that pace or prioritize margin expansion will affect competitive dynamics in molecular diagnostics.
The private structure may also accelerate eventual deal-making. Private equity firms operate on exit timelines, and Hologic's future sale or IPO could reshape the sector again. Near-term, the industry will watch for leadership changes, restructuring announcements, and signals on Panther menu development, particularly in respiratory and sexual health panels.